Skip to main content
Skip to main content
Normal
Press Release RSS Feed (opens in new window)
Press Releases
Press release year list
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
October 1, 2026
Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
October 1, 2026
Novocure to Report Third Quarter 2026 Financial Results
September 2, 2026
Novocure Announces Upcoming Investor Events
July 23, 2026
Novocure Reports Second Quarter 2026 Financial Results
July 1, 2026
Novocure to Report Second Quarter 2026 Financial Results
June 30, 2026
Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
June 18, 2026
Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
April 30, 2026
Novocure Reports First Quarter 2026 Financial Results
April 1, 2026
Novocure to Report First Quarter 2026 Financial Results
March 26, 2026
Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
March 2, 2026
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
February 27, 2026
Novocure to Participate in 2026 Leerink Global Healthcare Conference
February 26, 2026
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
February 24, 2026
Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)
February 11, 2026
U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
January 12, 2026
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update